Efficacy of aprepitant in the prevention of cisplatin-induced nausea and vomiting

LI Ai-jie; TAO Hai-tao; WANG Jin-liang; DONG Wei-wei; LI Rui-xin; HU Yi

Abstract：Objective:To observe the efifcacy of aprepitant in the prevention of the acute and delayed nausea and vomiting induced by cisplatin. Methods: A total of 100 cancer patients who received cisplatin (75 mg·m-2) in our hospital from January 1, 2014 to October 1, 2014 were enrolled. The antiemetic regimen for aprepitant group consisted of aprepitant, 5-HT3 receptor antagonist and dexamethasone;regimen for control group was 5-HT3 receptor antagonist and dexamethasone. The primary endpoints were the percentage of patients with a complete response (CR:no nausea and no salvage treatment) during the acute phase (day 1) and the delayed phase (days 2–5). The secondary endpoint was the percentage of patients without severe nausea during the entire study period (5 days) with chemotherapy. Results: There was no statistical differences in CR rates of acute phase between two groups (CR:70%vs 54%, P=0.149). The efifcacy of aprepitant group was better than that of control group in delayed phase (CR:78%vs 46%, P=0.002). The percentages of patients with no severe nausea during the entire study period in aprepitant group and control group were 86%and 62%(P=0.012), respectively. There were not signiifcant differences between two groups in respect of adverse reactions. Conclusion: Due to the good efifcacy and safety, the triple therapy containing aprepitant can be recommended for the prevention of cisplatin-induced nausea and vomiting.